IP Library Granted Patent US 12,735,447
Granted Patent B2
US 12,735,447 · App. 18/701,763 · Granted Sep 15, 2026

Process for preparing b-[(7α, 17β)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-trien-3-yl]-boronic acid and process intermediates

Inventors: Roberto Lenna (S. Giorgio su Legnano, IT); Andrea Fasana (Nesso, IT)
Assignee: Industriale Chimica S.R.L.
C07J31/006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,735,447
App. No.
18/701,763
Granted
Sep 15, 2026
Kind
B2
Abstract

The present invention relates to a process for preparing B-[(7α,17β)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-trien-3-yl]-boronic acid, also known as Fulvestrant-3-boronic acid or ZB716, whose structure is shown below:

Claims (19)

1 . A process for the synthesis of B-[(7α,17β)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5 (10)-trien-3-yl]-boronic acid (compound ZB716), comprising the following steps:

a) reaction of Fulvestrant, (7α,17β)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-estra-1,3,5 (10)-trien-3,17-diol, intermediate N-7 of the process, with a triflating agent, to obtain intermediate N-6, (7α, 17β)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-estra-1,3,5 (10)-trien-17-ol 3-triflate:

b) reaction of intermediate N-6 with an acylating reagent to obtain an intermediate of general formula N-5,

wherein R is selected from a linear or branched C1-C7 alkyl radical, an aromatic radical and a heterocyclic radical;

c) reaction of intermediate N-5 with 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi-1,3,2-dioxaborolane to obtain the intermediate of general formula N-4,

d) reaction of intermediate N-4 with an inorganic base to give the mixture made of intermediate N-3, (7α, 17β)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-estra-1,3,5 (10)-trien-17-ol, and compound ZB716, B-[(7α, 17β)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5 (10)-trien-3-yl]-boronic acid:

e) reaction of the mixture made of intermediate N-3 and compound ZB716 with KHF 2 to obtain intermediate N-1, potassium (7α,17β)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-estra-1,3,5 (10)-trien-17-ol-3-trifluoroborate:

f) treatment of intermediate N-1 with an inorganic base to give compound ZB716, B-[(7α, 17β)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5 (10)-trien-3-yl]-boronic acid:

2 . The process according to claim 1 wherein R=—CH 3 , in step b) is produced intermediate N-5′, (7α,17β)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-estra-1,3,5 (10)-trien-17-acetate 3-triflate, having the following formula:

and in step c), intermediate N-4′, (7α,17β)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-estra-1,3,5 (10)-trien-17-acetate is produced, having the following formula:

3 . The process according to claim 1 , wherein in step a) an aromatic bis(trifluoromethanesulfonimide) of general formula Ar—N(Tf) 2 is used as triflating agent, wherein Ar indicates the aromatic or heteroaromatic radical and the N(Tf) 2 group is the radical:

4 . The process according to claim 1 , wherein said triflating agent is 1,1,1-trifluoro-N-phenyl-N-[(trifluoromethyl)sulfonyl]methanesulfonamide.

5 . The process according to claim 1 , wherein the acylating agent of step b) is acetic anhydride.

6 . A compound (7α, 17β)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-estra-1,3,5 (10)-trien-17-acyloxy 3-triflate, of general formula:

wherein R is selected from a linear or branched C1-C7 alkyl radical, an aromatic radical and a heterocyclic radical.

7 . The compound N-5′ according to claim 6 , wherein R═—CH 3

8 . The compound (7α, 17β)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-estra-1,3,5 (10)-trien-17-acyloxy, of general formula:

wherein R is selected from a linear or branched C1-C7 alkyl radical, an aromatic radical and a heterocyclic radical.

9 . The compound N-4′ according to claim 8 , wherein R═—CH 3

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2024
From: LENNA, ROBERTO; FASANA, ANDREA
To: INDUSTRIALE CHIMICA S.R.L
Reel/Frame 067171/0645 →
Continuity (1)
Related Publication 20250136637A1 · May 1, 2025
References Cited (6)
US 10112962B2 · Wang · 2018 [cited by examiner]
US 20240174711A1 · Lenna · 2024 [cited by examiner]
US 20240218013A1 · Lenna · 2024 [cited by examiner]
International Search Report and Written Opinion for International Application No. PCT/IB2021/060016, dated Aug. 5, 2022, 14 pages. [cited by applicant]
Eve J. Brazier, Philip J. Hogan, et al. Fulvestrant: From the Laboratory to Commercial-Scale Manufacture. Organic Process Research & Development 2010, 14, 544-552. [cited by applicant]
Jiawang Liu et al, Fulvestrant-3 boronic acid (ZB716): an orally bioavailable selective estrogen receptor downregulator (SERD). J. Med. Chem. 2016, 59, 17, 8134-8140. [cited by applicant]